186 related articles for article (PubMed ID: 18930804)
1. Development of glycopeptide-intermediate resistance by Staphylococcus aureus leads to attenuated infectivity in a rat model of endocarditis.
Majcherczyk PA; Barblan JL; Moreillon P; Entenza JM
Microb Pathog; 2008; 45(5-6):408-14. PubMed ID: 18930804
[TBL] [Abstract][Full Text] [Related]
2. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital.
Garnier F; Chainier D; Walsh T; Karlsson A; Bolmström A; Grelaud C; Mounier M; Denis F; Ploy MC
J Antimicrob Chemother; 2006 Jan; 57(1):146-9. PubMed ID: 16286482
[TBL] [Abstract][Full Text] [Related]
3. Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis.
Weidenmaier C; Peschel A; Xiong YQ; Kristian SA; Dietz K; Yeaman MR; Bayer AS
J Infect Dis; 2005 May; 191(10):1771-7. PubMed ID: 15838806
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Fourier transform infrared spectroscopy for the rapid identification of glycopeptide-intermediate Staphylococcus aureus.
Amiali NM; Mulvey MR; Berger-Bächi B; Sedman J; Simor AE; Ismail AA
J Antimicrob Chemother; 2008 Jan; 61(1):95-102. PubMed ID: 17962217
[TBL] [Abstract][Full Text] [Related]
5. Experimental study on the efficacy of combinations of glycopeptides and beta-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides.
Domenech A; Ribes S; Cabellos C; Taberner F; Tubau F; Domínguez MA; Montero A; Liñares J; Ariza J; Gudiol F
J Antimicrob Chemother; 2005 Oct; 56(4):709-16. PubMed ID: 16120625
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model.
Hegde SS; Difuntorum S; Skinner R; Trumbull J; Krause KM
J Antimicrob Chemother; 2009 Apr; 63(4):763-6. PubMed ID: 19155225
[TBL] [Abstract][Full Text] [Related]
7. Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit.
de Lassence A; Hidri N; Timsit JF; Joly-Guillou ML; Thiery G; Boyer A; Lable P; Blivet A; Kalinowski H; Martin Y; Lajonchere JP; Dreyfuss D
Clin Infect Dis; 2006 Jan; 42(2):170-8. PubMed ID: 16355325
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin-intermediate Staphylococcus aureus selected during vancomycin therapy of experimental endocarditis are not detected by culture-based diagnostic procedures and persist after treatment arrest.
Moreillon P; Bizzini A; Giddey M; Vouillamoz J; Entenza JM
J Antimicrob Chemother; 2012 Mar; 67(3):652-60. PubMed ID: 22167243
[TBL] [Abstract][Full Text] [Related]
9. The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden.
Hurdle JG; O'Neill AJ; Chopra I
J Antimicrob Chemother; 2004 Jan; 53(1):102-4. PubMed ID: 14657089
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
Jacqueline C; Amador G; Batard E; Le Mabecque V; Miègeville AF; Biek D; Caillon J; Potel G
J Antimicrob Chemother; 2011 Apr; 66(4):863-6. PubMed ID: 21393213
[TBL] [Abstract][Full Text] [Related]
11. Strain-specific expression levels of pbp4 exist in isolates of glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA.
Wootton M; Bennett PM; MacGowan AP; Walsh TR
Antimicrob Agents Chemother; 2005 Aug; 49(8):3598-9. PubMed ID: 16048995
[No Abstract] [Full Text] [Related]
12. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?
Sakoulas G; Eliopoulos GM; Moellering RC; Novick RP; Venkataraman L; Wennersten C; DeGirolami PC; Schwaber MJ; Gold HS
J Infect Dis; 2003 Mar; 187(6):929-38. PubMed ID: 12660939
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effectiveness of common hospital hand disinfectants against methicillin-resistant Staphylococcus aureus, glycopeptide-intermediate S. aureus, and heterogeneous glycopeptide-intermediate S. aureus.
Wootton M; Walsh TR; Davies EM; Howe RA
Infect Control Hosp Epidemiol; 2009 Mar; 30(3):226-32. PubMed ID: 19199533
[TBL] [Abstract][Full Text] [Related]
14. Glycopeptide resistant Staphylococcus.
Witte W
J Vet Med B Infect Dis Vet Public Health; 2004; 51(8-9):370-3. PubMed ID: 15525368
[TBL] [Abstract][Full Text] [Related]
15. Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus.
del Río A; García-de-la-Mària C; Entenza JM; Gasch O; Armero Y; Soy D; Mestres CA; Pericás JM; Falces C; Ninot S; Almela M; Cervera C; Gatell JM; Moreno A; Moreillon P; Marco F; Miró JM;
Antimicrob Agents Chemother; 2016 Jan; 60(1):478-86. PubMed ID: 26525803
[TBL] [Abstract][Full Text] [Related]
16. MsrR contributes to cell surface characteristics and virulence in Staphylococcus aureus.
Hübscher J; McCallum N; Sifri CD; Majcherczyk PA; Entenza JM; Heusser R; Berger-Bächi B; Stutzmann Meier P
FEMS Microbiol Lett; 2009 Jun; 295(2):251-60. PubMed ID: 19459977
[TBL] [Abstract][Full Text] [Related]
17. Reduced expression of the atl autolysin gene and susceptibility to autolysis in clinical heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA) and GISA strains.
Wootton M; Bennett PM; MacGowan AP; Walsh TR
J Antimicrob Chemother; 2005 Nov; 56(5):944-7. PubMed ID: 16157619
[TBL] [Abstract][Full Text] [Related]
18. Staphylococcus aureus with decreased susceptibility to glycopeptides in cystic fibrosis patients.
Filleron A; Chiron R; Reverdy ME; Jean-Pierre H; Dumitrescu O; Aleyrangues L; Counil F; Jumas-Bilak E; Marchandin H
J Cyst Fibros; 2011 Sep; 10(5):377-82. PubMed ID: 21636331
[TBL] [Abstract][Full Text] [Related]
19. Staphylococcus aureus menD and hemB mutants are as infective as the parent strains, but the menadione biosynthetic mutant persists within the kidney.
Bates DM; von Eiff C; McNamara PJ; Peters G; Yeaman MR; Bayer AS; Proctor RA
J Infect Dis; 2003 May; 187(10):1654-61. PubMed ID: 12721946
[TBL] [Abstract][Full Text] [Related]
20. Role of sigmaB in the expression of Staphylococcus aureus cell wall adhesins ClfA and FnbA and contribution to infectivity in a rat model of experimental endocarditis.
Entenza JM; Moreillon P; Senn MM; Kormanec J; Dunman PM; Berger-Bächi B; Projan S; Bischoff M
Infect Immun; 2005 Feb; 73(2):990-8. PubMed ID: 15664942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
